Browse drugs

…ple with T2DM and established CVD to receive either the SGLT2i, empagliflozin, or placebo.5 To be eligible for this study, people had to meet…

…de (25 936), empagliflozin (715 802), sitagliptin (493 563) and glipizide (832 295) ( online supplemental eTable 1, 5–8). Baseline charac…

…all-cause mortality occurred in 551 out of 13,239 (4.2%) in the empagliflozin group and 6,589 out of 49,264 (13.4%) in the active control gro…

…liflozin 10 mg orally once daily, initiated 4 weeks after TAVI. Empagliflozin treatment will continue throughout the study period. Participan…

…atide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from 1 December 2017 to 31 December 2023 were included. The as…

…ndomly allocated 1:1:1 to receive liraglutide, empagliflozin or linagliptin treatment. The primary outcome measure is the efficacy differen…

…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …

…=111,357; e.g., empagliflozin, dapagliflozin, canagliflozin) or DPP4is (n=43,868; e.g., sitagliptin, linagliptin) without cross-exposu…

…201276042) of RCTs comparing SGLT2 inhibitors (dapagliflozin or empagliflozin) against placebo in HFpEF (LVEF >40%). To minimise reporting bi…

… regardless of administration route.These findings suggest that EMPA exerts antifibrotic and anti-inflammatory effects and may repre…

… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…